22UA:ETR
BioNTech SE - ADR
80,50 €
arrow_downward
-0,06%(-0,050) 1D
16 tet, 1:07:54 m.d., GMT+2 · EUR
search
TĂ« gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për 22UA...
Hap
80,75 €
I lartë
81,15 €
I ulët
80,45 €
Kapitalizimi i tregut
22,66Â mld
VĂ«llimi mesatar
26,41 mijë
VĂ«llimi
4,62 mijë
Maksimumi 52-javor
105,70 €
Minimumi 52-javor
68,30 €
Numri i punonjësve
8 mijë
Hap
80,75 €
I lartë
81,15 €
I ulët
80,45 €
Kapitalizimi i tregut
22,66Â mld
VĂ«llimi mesatar
26,41 mijë
VĂ«llimi
4,62 mijë
Maksimumi 52-javor
105,70 €
Minimumi 52-javor
68,30 €
Numri i punonjësve
8 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
ad-hoc-news.de
·
18 orë më parë
Canaccord cuts target for BioNTech stock to USD 132.00
Pluang
·
1 ditë më parë
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
2 ditë më parë
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TipRanks
·
2 ditë më parë
BioNTech Presses Ahead With BNT113 Cancer Trial After Initial Endpoint Miss
Profili
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Rreth BioNTech SE - ADR